본문 바로가기

바이오스펙테이터

기사본문

Novartis Korea-DeepNoid, “Developing AI solution for ankylosing spondylitis”

입력 2020-07-06 10:31 수정 2020-07-06 10:31

by Jongwon Jang

Signing a Memorandum of Understanding (MOU)..Analyzing the progress of ankylosing spondylitis disease and the quantitative amount of treatment response

Novartis Korea will develop an artificial intelligence solution that quantitatively analyzes the disease prognosis and treatment response of patients with ankylosing spondylitis by working with artificial intelligence medical solution company, DeepNoid.

For the purpose of research, etc., Novartis Korea and DeepNoid recently announced on the 30th that they have signed an MOU with the development of an artificial intelligence solution applicable to ankylosing spondylitis.

In particular, the core of this collaborative research is the construction of artificial image-based medical image analysis software applicable to actual patients in order to evaluate the course of disease progression and treatment response of ankylosing spondylitis more rapidly and accurately and to objectively compare and monitor the progress of the disease visually.

After collecting and analyzing the data of patients with ankylosing spondylitis and going through the process of developing an automated analysis algorithm for lesions, software for objectively analyzing medical images such as X-rays will be developed and expanded to clinical use.

GM of Novartis Korea, Joshi Venugopal, said “This collaboration is a partnership between Novartis, seeking for digital innovation in many aspects of the medical technology ecosystem, and DeepNoid, having high-quality medical AI technology. And I hope that an innovative solution will be created to the clinical field of spinal arthritis, where early diagnosis and treatment evaluation are still limited using medical images.”

"This collaboration with Novartis, a global pharmaceutical company, made us expand our business beyond image analysis and diagnostic assistance technology to monitoring and predicting treatment results through artificial intelligence." said Choi Woo-sik, CEO of DeepNoid. "By utilizing Novartis' global clinical research network, we will apply solutions developed at actual clinical sites and lay the foundation for global clinical verification." he added.

Meanwhile, DeepNoid is a bio-IT convergence company that developed DEEP:PHI, a medical video analysis platform in which medical staffs participate based on artificial intelligence technology, and is developing AI analysis algorithms for various diseases such as cerebral aneurysm and pulmonary nodules.

카카오스토리로 기사 공유하기